Abbott slides as Goldman cuts target, recall overhang weighs on sentiment
Abbott Laboratories shares fell about 3% as investors reacted to a major price-target cut while the company remains under heightened scrutiny tied to FreeStyle Libre 3/Libre 3 Plus sensor recall risks. The FDA has said the recall is associated with 860 serious injuries and seven deaths reported by Abbott as of January 7, 2026.
1. What’s moving the stock
Abbott Laboratories (ABT) traded lower Friday as sentiment turned risk-off following a notable analyst price-target cut, with investors also continuing to discount ongoing regulatory and litigation overhang tied to the FreeStyle Libre CGM franchise. Goldman Sachs kept a Buy rating but lowered its price target to $121 from $140, a reset that can pressure near-term positioning when the stock is already trading near recent lows. (gurufocus.com)
2. Recall and regulatory overhang remains a key pressure point
Abbott’s diabetes-care business has faced elevated scrutiny after the FDA posted a Class I recall notice covering certain FreeStyle Libre 3 and FreeStyle Libre 3 Plus sensors due to the risk of inaccurate readings that can lead to inappropriate treatment decisions. The FDA said Abbott reported 860 serious injuries and seven deaths associated with the issue as of January 7, 2026, reinforcing why the Libre narrative can dominate risk discussions even on days when the immediate catalyst is analyst action. (fda.gov)
3. Why this matters now (near-term setup)
With the stock under pressure into mid-April, investors are focusing on whether Abbott can stabilize confidence in Libre manufacturing/quality controls and avoid incremental recall expansion or additional regulatory escalation. Separately, Abbott is also digesting its large strategic push in diagnostics after completing the Exact Sciences acquisition in late March, which increases execution risk and can amplify sensitivity to any negative headlines. (markets.financialcontent.com)